
|Videos|July 19, 2016
Charles Ryan, MD: Comparison of Chemotherapy to a Secondary Hormone at the Time of Progression
Advertisement
Episodes in this series

At the time of progression, would you go back to chemotherapy or use a secondary hormone?
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- Digital rectum exam revealed nodular prostate /L
- Serum PSA level; 129 ng/ml
- Alkaline phosphatase, 258
- TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
- CT indicates blastic lesions to lumbar spine and pelvis
- Bone Scan positive for T/L spine, pelvis, right femur, scapula
- ECOG performance status, 1
Advertisement
Related to this article

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5










